Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

MicroRNA profile in very young women with breast cancer.

Peña-Chilet M, Martínez MT, Pérez-Fidalgo JA, Peiró-Chova L, Oltra SS, Tormo E, Alonso-Yuste E, Martinez-Delgado B, Eroles P, Climent J, Burgués O, Ferrer-Lozano J, Bosch A, Lluch A, Ribas G.

BMC Cancer. 2014 Jul 21;14:529. doi: 10.1186/1471-2407-14-529.

2.

Concordance of genomic alterations between primary and recurrent breast cancer.

Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM.

Mol Cancer Ther. 2014 May;13(5):1382-9. doi: 10.1158/1535-7163.MCT-13-0482. Epub 2014 Mar 7.

3.

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.

Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA.

Clin Cancer Res. 2014 Apr 1;20(7):1757-1767. doi: 10.1158/1078-0432.CCR-13-2332. Epub 2014 Jan 7.

4.

High stability of microRNAs in tissue samples of compromised quality.

Peiró-Chova L, Peña-Chilet M, López-Guerrero JA, García-Giménez JL, Alonso-Yuste E, Burgues O, Lluch A, Ferrer-Lozano J, Ribas G.

Virchows Arch. 2013 Dec;463(6):765-74. doi: 10.1007/s00428-013-1485-2. Epub 2013 Oct 3.

PMID:
24197449
5.

High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients.

Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, Hortobágyi GN.

Oncologist. 2012;17(6):766-74. doi: 10.1634/theoncologist.2011-0377. Epub 2012 May 14.

6.

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.

Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramírez-Merino N, Lobo F, Bellosillo B, Corominas JM, Yelamos J, Serrano S, Lluch A, Rovira A, Albanell J.

Ann Oncol. 2012 May;23(5):1156-64. doi: 10.1093/annonc/mdr361. Epub 2011 Sep 9.

PMID:
21908496
7.

Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer.

Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Ferrer-Lozano J, Lluch A, Niikura N, Bartholomeusz C, Nakamura S, Hortobagyi GN, Ueno NT.

Oncologist. 2011;16(7):956-65. doi: 10.1634/theoncologist.2010-0409. Epub 2011 Jun 28.

8.

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF.

JAMA. 2011 May 11;305(18):1873-81. doi: 10.1001/jama.2011.593.

9.

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F.

Mol Cancer Ther. 2011 Jun;10(6):1093-101. doi: 10.1158/1535-7163.MCT-10-1089. Epub 2011 Apr 13.

10.

[Multiple analysis of morphologic factors with prognostic value in transitional cell papillary carcinoma of the bladder. Retrospective study of 571 cases].

Ramos Soler D, Ferrer Lozano J, Navarro Fos S, Llombart-Bosch A.

Actas Urol Esp. 1999 Feb;23(2):119-26. Spanish.

PMID:
10327675

Supplemental Content

Loading ...
Support Center